NCT01892020 - Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 50

Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.

DRUG

biphasic human insulin 50

Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.

Trial Locations (1)

100034

Beijing